MedTrace Logo

An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer

NCT01725386 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 274

Last updated 2016-09-28

Study results available
· View outcomes & findings →

Summary

This observational study will evaluate the routine clinical use and the safety and efficacy of capecitabine (Xeloda®) in participants with metastatic or advanced breast cancer. Eligible participants will be followed for up to 24 months.

Conditions

Interventions

DRUG

Capecitabine

Oral tablet(s) administered according to prescribing information

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01725386 on ClinicalTrials.gov